Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Rectal Neoplasms 20Colonic Neoplasms 20Carcinoma, Renal Cell 17Fallopian Tube Neoplasms 15Breast Neoplasms 13Ovarian Neoplasms 12Colorectal Neoplasms 12Carcinoma, Non-Small-Cell Lung 12Brain Neoplasms 10Neoplasms 9Glioblastoma 9Brenner Tumor 8Squamous Cell Carcinoma of Head and Neck 7Prostatic Neoplasms 7Pancreatic Neoplasms 7Melanoma 7Oligodendroglioma 6Gliosarcoma 6Glioma 6Breast Neoplasms, Male 6Adenocarcinoma of Lung 6Lung Neoplasms 5Carcinoma, Ovarian Epithelial 5Astrocytoma 5Adenocarcinoma, Bronchiolo-Alveolar 5Uterine Cervical Neoplasms 4Salivary Gland Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Carcinoma, Hepatocellular 4Unspecified Adult Solid Tumor, Protocol Specific 3

Interventions

veliparib 1tipifarnib 1pazopanib 1Mitozytrex 1Mitomycin 1Immunoglobulin G 1Erlotinib Hydrochloride 1Disulfides 1Bevacizumab 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Solid Neoplasm × Bevacizumab × Clear all
NCT01749384 2017-10-12

Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1 Completed
12 enrolled

Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡